Key takeaways for California
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • Medi-Cal coverage rules apply for Insulin Resistance patients in California — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
California-specific context
California has telehealth access concentrated in Los Angeles, San Diego, San Jose metros, with additional reach to San Francisco and Fresno. Kaiser Permanente, UCSF, Stanford Health, UCLA Health, Cedars-Sinai is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.cdph.ca.gov.
Californiatelehealth & pricing rules
- • California requires a live video consultation before a GLP-1 prescription.
- • California allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in California: ~$285/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.